OTC Observer Inc reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market

Sponsored Financial Content

Daniel Gedeon Teper Acquires 39,400 Shares of Immune Pharmaceuticals Inc $IMNP Stock


Immune Pharmaceuticals Inc (NASDAQ:IMNP) CEO Daniel Gedeon Teper acquired 39,400 shares of the firm’s stock in a transaction that occurred on Tuesday, January 12th. The shares were bought at an average price of $0.62 per share, for a total transaction of $24,428.00. Following the completion of the purchase, the chief executive officer now owns 4,724,705 shares in the company, valued at approximately $2,929,317.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Daniel Gedeon Teper also recently made the following trade(s):
  • On Tuesday, January 5th, Daniel Gedeon Teper acquired 62,000 shares of Immune Pharmaceuticals stock. The shares were bought at an average price of $0.81 per share, for a total transaction of $50,220.00.

Today’s Trading

Immune Pharmaceuticals Inc (NASDAQ:IMNP) opened at 0.55 on Thursday. Immune Pharmaceuticals Inc has a 12 month low of $0.51 and a 12 month high of $2.28. The company’s market capitalization is $16.65 million. The stock’s 50 day moving average price is $0.77 and its 200 day moving average price is $1.28.
Immune Pharmaceuticals (NASDAQ:IMNP) last released its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by $0.17. Equities research analysts anticipate that Immune Pharmaceuticals Inc will post ($0.63) earnings per share for the current fiscal year.

Analyst Ratings

IMNP has been the topic of a number of research analyst reports. FBR & Co. restated an “outperform” rating on shares of Immune Pharmaceuticals in a research note on Friday, October 30th. Chardan Capital upped their target price on Immune Pharmaceuticals from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Finally, Roth Capital started coverage on Immune Pharmaceuticals in a research note on Thursday, October 8th. They issued a “buy” rating and a $6.00 target price on the stock.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc. is a United States-based clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics, including monoclonal antibodies, nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. Its pipeline includes, Bertilimumab, which is a clinical-stage human antibody, targeting eotaxin-1, which is involved in a number of immune mediated diseases; NanomAbs, which is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells, and AmiKet, which is a topical neuropathic pain drug candidate. The Company’s oncology pipeline includes Crolibulin, which is a small molecule vascular disrupting agent and apoptosis inducer for the intended treatment of patients with solid tumors, and Azixa, which is a vascular disruptive agent in development for the treatment of primary brain cancers and metastatic tumors with brain involvement.
12 Month Chart for NASDAQ:IMNP

No comments:

Post a Comment

Advertisement